CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionP/E ratio is 212.02×, higher than 95% of its Medical Devices peers (median 31.47×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.20%Below 5Y avg (0.81%)
Annual Rate
CNY 0.20Paid annual
Payout Ratio
44.4%Sustainable
Last Ex-Dividend
May 29, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.46BCNY961.40M · vs all stocks (USD)
Trailing P/E
212.02xvs Medical Devices peers
Revenue (TTM)
404.51MCNY60.15M · vs all stocks (USD)
Profit Margin
6.85%vs Medical Devices peers
52-Week Change
-26.14%vs all stocks
Market Capitalization
6.46BCNY961.40M · vs all stocks (USD)
Enterprise Value
6.11BCNY908.69M · vs all stocks (USD)
Trailing P/E
212.02xvs Medical Devices peers
Price to Sales (TTM)
14.98xvs Medical Devices peers
Price to Book (MRQ)
7.39xvs Medical Devices peers
Enterprise to Revenue
15.11xvs Medical Devices peers
Enterprise to EBITDA
71.79xvs Medical Devices peers
Gross Margin
56.66%vs Medical Devices peers
Profit Margin
6.85%vs Medical Devices peers
Operating Margin
15.19%vs Medical Devices peers
Return on Assets (TTM)
1.54%vs Medical Devices peers
Return on Equity (TTM)
3.37%vs Medical Devices peers
Revenue (TTM)
404.51MCNY60.15M · vs all stocks (USD)
Revenue per Share (TTM)
6.57CNYUpdated Aug 21, 2026Quarterly Revenue Growth
4.30%vs Medical Devices peers
Gross Profit (TTM)
238.66MCNY35.49M · vs all stocks (USD)
EBITDA (TTM)
83.43MCNY12.41M · vs all stocks (USD)
Net Income (TTM)
27.71MCNY4.12M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
56.70%vs Medical Devices peers
Operating Cash Flow (TTM)
86.95MCNY12.93M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
35.30MCNY5.25M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2000CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.20%vs all stocks
5-Year Average Dividend Yield
0.81%vs all stocks
Payout Ratio
44.44%vs Medical Devices peers
Revenue
398.40MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
165.62MCNYFY2025 · Dec 31, 2025Gross Profit
232.78MCNYFY2025 · Dec 31, 2025Operating Income
19.92MCNY2.96M · vs all stocks (USD)
Pre-tax Income
24.82MCNYFY2025 · Dec 31, 2025Income Tax Expense
1.62MCNYFY2025 · Dec 31, 2025Net Income
23.20MCNYFY2025 · Dec 31, 2025EBIT
26.97MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
83.43MCNYFY2025 · Dec 31, 2025Research & Development
47.76MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
45.33MCNYFY2025 · Dec 31, 2025Other Operating Expenses
8.45MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
455.27KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.15MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3700CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3700CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
62.70MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
62.70MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
23.20MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
24.87MCNYFY2025 · Dec 31, 2025Free Cash Flow
-25.57MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
58.69MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
23.20MCNYFY2025 · Dec 31, 2025Other Non-cash Items
6.88MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-11.41MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
6.20MCNYFY2025 · Dec 31, 2025Capital Expenditures
-50.45MCNYFY2025 · Dec 31, 2025Net Acquisitions
23.51KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-50.42MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
115.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-185.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-20.79MCNYFY2025 · Dec 31, 2025Other Financing Charges
4.89MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-85.90MCNYFY2025 · Dec 31, 2025Shares Outstanding
63.48MSharesUpdated Aug 21, 2026Float Shares
35.08MSharesUpdated Aug 21, 2026% Held by Insiders
76.06%vs all stocks
% Held by Institutions
3.01%vs all stocks
Total Cash (MRQ)
64.86MCNY9.65M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.01CNYUpdated Aug 21, 2026Total Debt (MRQ)
32.07MCNY4.77M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0386xvs Medical Devices peers
Current Ratio (MRQ)
2.95xvs Medical Devices peers
Book Value per Share (MRQ)
12.91CNYUpdated Aug 21, 2026Total Assets
931.30MCNY138.49M · vs all stocks (USD)
Total Current Assets
235.79MCNYFY2025 · Dec 31, 2025Total Liabilities
111.30MCNYFY2025 · Dec 31, 2025Total Non-current Assets
695.51MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
2.76MCNYFY2025 · Dec 31, 2025Total Current Liabilities
108.54MCNYFY2025 · Dec 31, 2025Cash
58.69MCNYFY2025 · Dec 31, 2025Cash Equivalents
4.65MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
63.34MCNYFY2025 · Dec 31, 2025Accounts Receivable
55.96MCNYFY2025 · Dec 31, 2025Inventory
107.08MCNYFY2025 · Dec 31, 2025Accounts Payable
14.02MCNYFY2025 · Dec 31, 2025Short-term Debt
46.24MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.31MCNYFY2025 · Dec 31, 2025Long-term Debt
1.15MCNYFY2025 · Dec 31, 2025Common Stock (Book)
63.48MCNYFY2025 · Dec 31, 2025Retained Earnings
178.55MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
820.01MCNY121.94M · vs all stocks (USD)
Treasury Stock
20.01MCNYFY2025 · Dec 31, 202552-Week Low
76.62CNYUpdated Aug 21, 202652-Week High
217.00CNYUpdated Aug 21, 202652-Week Change
-26.14%vs all stocks
50-Day MA
92.70CNYUpdated Aug 21, 2026200-Day MA
135.72CNYUpdated Aug 21, 2026Avg 10-Day Volume
640.25KSharesUpdated Aug 21, 2026Avg 30-Day Volume
619.09KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.4500CNYUpdated Aug 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
P/E ratio is 212.02×, higher than 95% of its Medical Devices peers (median 31.47×)Significant
P/E ratio: 212.022Industry median: 31.47Industry P95: 200.906Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.57Profit Margin: 0.07
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Tianjin Tianyao Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kura Oncology Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Youcare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Green Cross Corporation
Tier 1ProductionApproval-Gated PipelineRule
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Seegene, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Kanghua Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bide Pharmatech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Er-Kang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Annexon, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shandong Nanshan Fashion Co., Ltd.
3 interpretationsPartial Recovery After Sharp DeclinePrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Shanghai Film Co., Ltd.
3 interpretationsPartial Recovery After Sharp DeclinePrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Shanghai Jin Jiang Online Network Service Co., Ltd.
3 interpretationsPartial Recovery After Sharp DeclinePrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity